Login to Your Account



Pharma: Other News To Note


Wednesday, December 19, 2012
• Merck & Co. Inc., of Whitehouse Station, N.J., and GE Healthcare, of Princeton, N.J., inked a clinical study collaboration, license and supply agreement for the use of [18F]Flutemetamol, an investigational positron emission tomography imaging agent, to support Merck's development of MK-8931, an oral, beta-amyloid precursor protein site cleaving enzyme inhibitor in development for Alzheimer's disease.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription